Search results
Showing 1 to 14 of 14 results for palbociclib
Evidence-based recommendations on palbociclib (Ibrance) with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy.
Evidence-based recommendations on palbociclib (Ibrance) as initial endocrine-based therapy for hormone-receptor positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic (secondary) breast cancer in adults.
Evidence-based recommendations on abemaciclib (Verzenios) for treating locally advanced or metastatic, hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer in adults who have not had endocrine-based therapy before.
Evidence-based recommendations on ribociclib (Kisqali) as initial endocrine-based therapy for hormone-receptor positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic (secondary) breast cancer in adults.
Show all sections
Evidence-based recommendations on abemaciclib (Verzenios) with fulvestrant for hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy in adults.
Palbociclib for treating high-risk early breast cancer after neoadjuvant chemotherapy [ID3846]
Awaiting development [GID-TA10723] Expected publication date: TBC
Awaiting development [GID-TA10960] Expected publication date: TBC
Awaiting development [GID-TA11519] Expected publication date: TBC
Evidence-based recommendations on ribociclib (Kisqali) for treating hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer in adults who have had previous endocrine therapy.
Evidence-based recommendations on alpelisib (Piqray) with fulvestrant for treating hormone receptor-positive, HER2-negative, PIK3CA-mutated, locally advanced or metastatic breast cancer in adults.
Talazoparib for treating HER2-negative advanced breast cancer with germline BRCA mutations (TA952)
Evidence-based recommendations on talazoparib (Talzenna) for HER2-negative, locally advanced or metastatic breast cancer with germline BRCA1 or BRCA2 mutations in adults.
This guidance has been updated and replaced by NICE technology appraisal guidance 836.
In development [GID-TA11273] Expected publication date: TBC
NICE approves routine use of drug combination for advanced breast cancer
A life-extending drug combination for some people with advanced breast cancer will now be available for routine use in the NHS.